Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Praluent Coverage: Being First May Not Matter As Payers Await Repatha

Executive Summary

The pricing advantage that might have been available to Praluent as first-in-class is undercut by the fact that it only has about a month’s lead time over the competition.

You may also be interested in...

Priority Review Voucher Expansion Could Be Bad, Program Creator Says

Congress should be cautious about adding categories because more vouchers will mean a lower price for companies who want to sell them, Duke economist Ridley and Novartis exec Régnier argue.

Preferred Rivals: Express Scripts Covers Both Repatha And Praluent

Pharmacy benefit manager will cover both Amgen’s Repatha (evolocumab) and Regeneron/Sanofi’s Praluent(alirocumab) instead of picking a preferred PCSK9 inhibitor, as it did for hepatitis C.

Sanofi's Praluent And Amgen's Repatha Now Set For Battle In Europe, US

Praluent and Repatha are ready for a transatlantic showdown after regulatory approvals in Europe and US, but the jury remains out on which PCSK9 inhibitor will gain the upper hand.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts